EICHORCondition: Head and Neck Squamous Cell Carcinoma (HNSCC) · HNSCC · Sponsor: Sun Yat-sen University
Exploring the efficacy and safety of Tislelizumab combined with stereotactic body radiation therapy (SBRT) as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (HNSCC).
This description comes directly from the study's public registry record.
Chun-Yan Chen · 13826423812 · chenchuny@sysucc.org.cn
Ya-Ni Zhang · 15914271501 · zhangyn1@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06673693